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Oncogenic K-Ras upregulates ITGA6 expression via FOSL1
to induce anoikis resistance and synergizes with αV-Class
integrins to promote EMT
K Zhang1, S-M Myllymäki1,3, P Gao1, R Devarajan1, V Kytölä2, M Nykter2, G-H Wei1 and A Manninen1
In many cancer types, integrin-mediated signaling regulates proliferation, survival and invasion of tumorigenic cells. However, it is
still unclear how integrins crosstalk with oncogenes to regulate tumorigenesis and metastasis. Here we show that oncogenic
K-RasV12 upregulates α6-integrin expression in Madin–Darby canine kidney (MDCK) cells via activation of the mitogen-activated
protein kinase/extracellular signal-regulated kinase (ERK)/Fos-related antigen 1-signaling cascade. Activated α6-integrins promoted
metastatic capacity and anoikis resistance, and led to perturbed growth of MDCK cysts. Transcriptomic analysis of K-RasV12-
transformed MDCK cells also revealed robust downregulation of αV-class integrins. Re-expression of αV-integrin in K-RasV12-
transformed MDCK cells synergistically upregulated the expression of Zinc ﬁnger E-box-binding homeobox 1 and Twist-related
protein 1 and triggered epithelial-mesenchymal transition leading to induced cell motility and invasion. These results delineate the
signaling cascades connecting oncogenic K-RasV12 with α6- and αV-integrin functions to modulate cancer cell survival and
tumorigenesis, and reveal new possible strategies to target highly oncogenic K-RasV12 mutants.
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INTRODUCTION
Aberrant integrin-mediated cell–extracellular matrix (ECM) signal-
ing can contribute to the abnormal growth and morphology of
cancer cells.1–3 Polarized epithelial cells form extensive cell–cell
contacts (tight junctions, adherens junctions and desmosomes)
and cell–ECM contacts (focal adhesions and hemi-desmosomes),
all of which contribute to establishment of apical, lateral and basal
membrane domains each with distinct protein composition.4,5
Formation and maintenance of these polarized domains and
contacts is critical for regulating not only cell shape but also cell
growth, differentiation and survival. Therefore, it is not surprising
that loss of polarized organization within epithelial cancer tissues
correlates with the aggressiveness of the disease.6 Moreover, pre-
tumorigenic lesions can be formed by interfering with the
functions of cell polarity proteins, suggesting that polarity proteins
also serve a tumor suppressor function.7 In line with these
ﬁndings, polarized organization of surrounding epithelial cells can
suppress oncogenic properties of tumor cells.8,9 These studies
have shown that some but not all oncogenes have the ability to
escape suppression from the polarized environment when
surrounded by normal epithelial cells.9 How this is regulated is
still unclear.
The best-known examples of dual functions of polarity proteins
come from components of cell–cell adhesion complexes. E-cad-
herin at adherent’s junctions is frequently lost in invasive
cancers.10 In addition, E-cadherin targeting to adherens junctions
leads to stimulated growth.11 Similarly, cell–ECM interactions are
critical for cancer cell proliferation and invasion, but these
interactions are also complex and likely to be context dependent.
Integrins are important ECM receptors, which convey signals from
the ECM into cells to regulate and maintain epithelial cell growth,
survival and polarity.5,12,13 However, the speciﬁc integrin hetero-
dimers involved and the exact molecular mechanisms remain
uncertain. Non-canonical integrin-mediated signaling is often
reported in cancers.1–3,14
Transformed cancer cells can escape epithelial monolayer via
extrusion to apical or basolateral side.15 Although abnormal
growth signaling might allow survival of apically extruded tumor
cells without ECM contact, basolateral extrusion is generally
thought to promote potentiate spread and invasion of tumor cells
and eventually promote formation of metastatic lesions.10
Integrins are ideally positioned to convey signals and functions
required for escape of oncogenic cells from polarized epithelium.
Here we report that K-RasV12/ mitogen-activated protein kinase
(MAPK)/extracellular signal-regulated kinase (ERK)/Fos-related
antigen 1 (FOSL1)-signaling cascade activates α6-integrin expres-
sion, leading to anoikis resistance and increased metastatic
potential of K-RasV12-transformed cells. K-RasV12 transformation
also led to downregulation of αV-class integrins in Madin–Darby
canine kidney (MDCK) cells that are considered to be a model for
normal epithelial cells. We show that re-expression αV-integrin in
K-RasV12-MDCK cells is sufﬁcient to convert them into highly
invasive mesenchymal cells. This conversion was mediated via
autocrine activation of transforming growth factor (TGF)-β
signaling pathway leading to activation of epithelial-
mesenchymal transition (EMT) transcription factors Zinc ﬁnger
E-box-binding homeobox 1 (ZEB1), TWIST1 and Snail2. Taken
together, our ﬁndings demonstrate important and novel insight
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into the signaling cascades connecting oncogenic K-RasV12 with
α6- and αV-integrin functions to modulate cancer cell survival and
tumorigenesis, and reveal new possible strategies to target highly
oncogenic K-RasV12 mutants.
RESULTS
Oncogenic K-RasV12 transforms MDCK cells to enable their
extrusion and overcome tumor suppression by the surrounding
normal epithelium
Integrins are important ECM receptors that are critical for cancer
cell proliferation and invasion.1–3,5,12 Although integrin mutations
are rare in cancers and integrins do not directly transform
cells, they are often required for oncogene-induced tumorigenesis
and metastasis.1,3,16 However, the underlying molecular mechan-
isms remain uncertain. To address these mechanistic links, we ﬁrst
expressed different oncogenes in MDCK cells to assess their
ability to transform polarized epithelial cells. Three-dimensional
(3D) cultures of MDCK cells have been successfully used as a
model to examine abnormal cell growth and polarity, both of
which are features of tumorigenic cells.5,17 Activating mutations or
overexpression of HIF2α, Enhancer of zeste homolog 2, β-catenin,
K-Ras and H-Ras are particularly frequent in solid tumors.18–22
Overexpression of β-catenin4A, H-RasV12 or K-RasV12 all led to
severely compromised cyst formation resulting in cell clusters
with poorly polarized outer epithelial layer surrounding a mass
of non-polarized cells (Figures 1a and b). In contrast, HIF2α2A-
and Enhancer of zeste homolog 2-overexpressing MDCK
cells formed polarized cysts with single lumen with similar
frequency as wild-type (WT) parental MDCK cells (Figures 1a
and b).
Although on one hand, loss of epithelial polarity is a hallmark of
aggressive tumors, on the other hand, polarized epithelial cells are
remarkably resistant to transformation.8,9 Therefore, epithelial
organization per se has tumor-suppressing properties.23 Never-
theless, some oncogenes are capable of driving apical or
basolateral extrusion of transformed cancer cells away from the
tumor suppressing polarized epithelial monolayer (Supplementary
Figure 1).9,24 To focus our attention on strong oncogenes that
can overcome the suppressive polarized epithelial microenviron-
ment, we transformed individual cells in polarized MDCK cysts
with β-catenin4A, K-RasV12 or H-RasV12 and analyzed their
capacity to drive apical or basolateral cell extrusion or
outgrowth.9 MDCK cells were allowed to form polarized cysts
after which they were exposed to highly diluted lentivirus
preparations expressing either green ﬂuorescent protein (GFP)
alone or both GFP and K-RasV12, resulting in transduction of single
cells within cysts9 (Figure 1c). Five days after, viral transduction
cysts were ﬁxed and the growth of GFP-positive cells was analyzed
(Figures 1d and e). Long-term, time-lapse (48–60 h), live-cell
spinning disc confocal microscopy was used to follow how the
GFP-positive outgrowths formed (Figure 1f and Supplementary
Movies 1 and 2). Neither outgrowth nor extrusion was observed
for GFP-expressing cells (Figures 1d–f and Supplementary Movie
1). In contrast, K-RasV12-overexpressing cells proliferated rapidly
and formed bulging outgrowths within the epithelial layer and
were frequently extruded from the cysts either basally or apically
(Figures 1d–f and Supplementary Movie 2). In summary, K-RasV12
and H-RasV12 but not β-catenin4A expression enabled outgrowth
and extrusion of transformed cells, despite the surrounding
normal epithelium. K-RasV12 mutations are most frequently in
many cancers.18 Therefore, we focused our studies on the effects
of K-RasV12 expression on integrin-mediated cell–ECM signaling, in
order to reveal the escape mechanisms employed by the K-RasV12-
transformed cells.
The expression of the components mediating cell–ECM
interactions is modulated in K-RasV12-transformed MDCK cells
To study the genetic program underlying phenotypic changes in
K-RasV12-transformed cells, the steady-state mRNA expression
proﬁle was analyzed by using RNA sequencing (RNA-Seq) for both
WT- and K-RasV12-MDCK cells (Figure 2a and Supplementary
Table 1a). As expected, the PANTHER pathway ontology analysis
revealed multiple K-RasV12-induced changes in the MAP kinase
pathway components and its downstream targets, which are
involved in the regulation of cell proliferation and growth
(Figure 2b). Importantly, cell adhesion and cell–ECM interaction-
associated pathways, in which integrins are central nodes,
were among the major pathways highlighted in the analysis
(Figure 2b). ITGA6 was highly upregulated, whereas αV-class
integrin genes ITGAV, ITGB5, ITGB6 and ITGB8 were downregulated
(Figure 2a). RNA-Seq data on integrins was conﬁrmed using
quantitative PCR (qPCR) (Figure 2c). Moreover, western blot
analysis and ﬂuorescence-activated protein kinase (FACS) cell
surface analysis showed that the relatively low protein levels of
α6-integrins in WT-MDCK cells are robustly upregulated upon
expression of K-RasV12 but αV-integrins are downregulated
(Figures 2d and e). Previous studies have indicated that α6β4-
integrins promote tumorigenesis but α6β1-integrins inhibits
tumor progression.25–27 Whereas α6-integrin can pair with both
β1- and β4-integrins to form heterodimeric laminin receptors,28
only α6β4-integrins were detected in co-immunoprecipitation
assays in WT-MDCK and K-RasV12-MDCK cells (Supplementary
Figure 2a).
α6-integrin expression is required for K-RasV12-induced
transformation and lung metastasis
To study whether α6-integrin function is necessary for K-RasV12-
induced transformation and metastasis, we generated α6-integrin
knockout (α6-KO) MDCK cells using CRISPR/Cas9-technology
followed by overexpression of K-RasV12.29 Ablation of α6-integrin
expression was conﬁrmed by western blotting and FACS cell
surface analysis (Figures 3a and b). To assess the transforming
capacity of K-RasV12 expression, cells were seeded into soft agar
and grown for 15 days during which time WT-MDCK cells grew
slowly and formed only small foci due to lack of proper ECM
contact (Figure 3d). In contrast, K-RasV12-MDCK cells formed
multiple large cell clusters, indicating that they had acquired
resistance to anoikis. K-RasV12/α6-KO-MDCK cells had signiﬁcantly
reduced capacity to form colonies in soft agar when compared
with K-RasV12 cells (Figures 3d and e). The proto-oncogene c-Src
(Src) is a non-receptor tyrosine kinase protein, which is associated
with multiple aggressive cancers.30,31 Recent studies have
implicated Src tyrosine kinase as an important upstream activator
of K-Ras-mediated signaling.32,33 Integrin ligation is often asso-
ciated with activation of a dual kinase complex involving focal
adhesion kinase and Src.34 In order to examine whether Src-
activation is affected by depletion of α6-integrin, we studied the
levels of phosphorylated Src in the different cell lines. K-RasV12
efﬁciently induced Src phosphorylation that was completely
abolished upon depletion of α6 expression (Figure 3a). In addition,
β4-integrin is also required for the activation of Src by K-RasV12
(Supplementary Figure 2b). Strikingly, we observed that K-RasV12
was redistributed from lateral plasma membrane domain to
perinuclear vesicles in α6-KO cells (Figure 3c). Although Src
tyrosine phosphorylation was strongly inhibited, the total levels or
localization of Src protein remained unchanged (Figure 3c). To
investigate in vivo metastatic capacity of WT-, K-RasV12- and
K-RasV12/α6-KO-MDCK cells, they were injected into the tail veins
of immunocompromised NOD.CB17-PrkdcSCID mice. All mice
were killed 15 days later, except for three K-RasV12-MDCK-injected
mice that had to be killed earlier due to their poor condition. As all
of the injected cells also expressed GFP, we measured the GFP
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ﬂuorescence in the freshly dissected lung tissues using in vivo
imaging system to evaluate the colonization of the lungs by the
injected cells (Figure 3f). Then, part of the samples were prepared
for cryosections and the remaining part for ﬁxation for parafﬁn
sections. Cryosections were imaged and the relative amounts of
GFP-positive areas representing metastatic lesions were deter-
mined (Figures 3f and g). K-RasV12-transformed MDCK cells had
colonized signiﬁcant parts of the lung tissue sections, whereas
only occasional GFP-positive cells were observed in the lungs of
mice injected with GFP-WT-MDCK cells (Figures 3f and g).
Importantly, when compared with K-RasV12-MDCK cells, the
K-RasV12/α6-KO-MDCK cells showed dramatically reduced lung
metastasis (Figures 3f and g). Same results were seen when
parafﬁn-embedded, hematoxylin and eosin-stained sections were
analyzed for the size of tumor cell colonies (Supplementary
Figure 6). Taken together, these data show that K-RasV12-induced
upregulation of α6-integrin expression is critical for oncogenic
K-RasV12 induced transformation and metastasis. Moreover, this
function involves activation of Src kinase that in turn is required to
maintain K-RasV12 at the cell surface.
Loss of α6-integrin inhibits anchorage-independent growth of
K-RasV12-transformed MDCK cells via suspension-induced
apoptosis
As stated above, reduction of α6-integrin decreased the number
of K-RasV12-MDCK cell colonies in soft agar assay and the
metastatic colonization in the lungs. Whereas α6-integrin expres-
sion was not essential for basal outgrowth or extrusion of
K-RasV12-transformed cells within polarized cysts, apical extrusion
was not observed (Supplementary Figure 3). To conﬁrm and
extend these results, we analyzed the growth of the different cell
lines in 3D cultures in more detail. It was found that, similar to WT-
MDCK cells, K-RasV12/α6-KO-MDCK cells formed visible lumens
when grown in 3D culture conditions, albeit with somewhat
slower kinetics WT-MDCK cells (Figure 4a). To assess the role of
anoikis in cystogenesis, the cysts were stained for active caspase-3
to label apoptotic cells. During the ﬁrst 3 days, rare apoptotic cells
were seen in the forming lumen of WT-MDCK cells (Figures 4a and b).
Apoptotic cells were not detected in K-RasV12-cell clusters but they
were abundant in the lumens of K-RasV12/α6-KO-MDCK cysts
analyzed at day 6, indicating that luminal cells are cleared by
Figure 1. K-RasV12-transformed MDCK cells can escape from tumor suppressive polarized epithelium. (a) Confocal images of WT MDCK cells or
MDCK cells transduced with HIF2α2A-, Enhancer of zeste homolog 2 (EZH2), β-catenin4A-, H-RasV12 or K-RasV12-expressing viral vectors and
cultured for 6 days in 3D Matrigel matrix. Nuclei were counterstained with 2-(4-amidinophenyl)-1H -indole-6-carboxamidine (DAPI) (blue)
and F-actin was visualized with Alexa488-phalloidin (green). (b) Quantiﬁcation of the cyst phenotypes. Data are presented as the mean± s.d.
and comes from three independent experiments (n= 100 for each condition). Statistical signiﬁcance was determined by two-tailed t-test.
*P-valueso0.05, **P-valueso0.01 and ***P-valueso0.001. (c) Schematic of the single-cell lentiviral infection experiment on polarized MDCK
cysts. Representative images (d) and quantiﬁcation (e) of clonal expansion of control (GFP only), β-catenin4A-, H-RasV12- or K-RasV12-transduced
(GFP-positive) cells imaged 5 days after infection. (f) Snapshots of time-lapse imaging of control (GFP, green) cells or K-RasV12-transformed
(K-RasV12, green) MDCK cells stably expressing H2B-mRFP to visualize nuclei. Imaging was started ~ 3 days after single-cell infection (indicated
as 0 h). Data are presented as the mean± s.d. and comes from three independent experiments. Scale bars= 50 μm (a, d and f).
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apoptosis in the absence of α6-integrins (Figures 4a and b). To
determine a role of α6-integrin in anoikis, we used ﬂow cytometry
to measure the percentage of apoptotic cells in WT-, K-RasV12,
K-RasV12/α6-KO-MDCK cells seeded onto polyHEMA-coated plates.
Loss of α6-integrin clearly increased the apoptotic cell population
in K-RasV12-expressing cells (Figures 4c and d). Western blot assay
of cleaved caspase-3 from polyHEMA-grown cells further con-
ﬁrmed that loss of α6-integrin promoted anoikis-induced cell
death in K-RasV12-expressing cells. Furthermore, we found that
K-RasV12-mediated inhibition of pro-apoptotic Bax expression was
reversed upon α6-KO in polyHEMA-grown cells (Figure 4e).
K-RasV12 upregulates α6-integrin expression via MAPK-mediated
activation of FOSL1
Next we investigated the mechanism how α6-integrin is
upregulated by K-RasV12. We tested small molecule inhibitors
targeting ERK (PD980259) and PI3K (Pictilisib), the two major
kinase cascades activated by the Ras pathway.35,36 It was observed
that PD980259 efﬁciently blocked the K-RasV12-induced expression
of α6-integrin (Figures 5a–c), whereas Pictilisib was without an
effect (Supplementary Figure 4). PD980259 downregulated α6-
integrin expression at both protein and mRNA level, suggesting a
transcriptional control mechanism (Figures 5a–d). To explore the
possible mechanisms of transcriptional regulation of α6-integrin
expression, we analyzed the RNA-seq data focusing on transcrip-
tion factors. MAPK/ERK pathway effectors, FOS and FOSL1, were
signiﬁcantly upregulated in K-RasV12-transformed MDCK cells
(Figure 2a and Supplementary Table 1a).37 Upregulation of the
gene products of FOS and FOSL1 was conﬁrmed by western
blotting (Figure 5e). Treatment of K-RasV12-MDCK cells with the
ERK inhibitor, PD980259, prevented upregulation of both FOS and
FOSL1 (Figure 5f). The promoter region of ITGA6 contain potential
binding sites for FOS and FOSL1. To study whether FOS or FOSL1
bind to the ITGA6 promoter region, we performed chromatin
immunoprecipitation assay followed by qPCR in WT- and
K-RasV12-MDCK cells. We found that in K-RasV12-MDCK cells, only
FOSL1 was enriched at the ITGA6 promoter region (Figure 5g).
Furthermore, our luciferase reporter assay demonstrated that
ITGA6 is a direct target of FOSL1 in MDCK cells (Figure 5h). To
conﬁrm a functional role for FOSL1, we used CRISPR/Cas9 to
knockout FOSL1 expression in K-RasV12-MDCK cells. In agreement
with the important role of FOSL1 in inducing ITGA6 transcription,
α6-integrin expression was not seen in K-RasV12/FOSL1-KO-MDCK
Figure 2. K-RasV12 modulates integrin expression proﬁle of transformed MDCK cells. (a) Heatmap representation of RNA-Seq analysis of WT-
and K-RasV12-MDCK cells showing differentially expressed transcripts (42-fold; Po0.05). Deeper color shows higher expression level. FPKM,
fragments per kilobase per million mapped fragments. (b) PANTHER pathway ontology analysis showing the most signiﬁcantly affected
biological processes modulated in K-RasV12-expressing cells (Po0.05). (c) qPCR analysis of the relative expression levels of selected integrin
subunits in WT and in K-RasV12-expressing MDCK cells. (d) Western blot analysis was performed to detect β1-integrin, β4-integrin, α6-integrin,
αV-integrin, HA (HA-K-RasV12) and tubulin in WT- and K-RasV12-MDCK cells. (e) FACS analysis of surface expressed α6-integrin in WT (blue)
and K-RasV12 (red) MDCK cells or αV-integrin in WT (blue) and K-RasV12 (red) MDCK cells. Unlabeled cells (only secondary antibody) are
shown in gray.
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Figure 3. α6-integrin is required for K-RasV12-induced anoikis resistance. (a) Western blot analysis of WT, K-RasV12 and two independent α6-KO/
K-RasV12-MDCK cell line lysates using antibodies against α6-integrin, β4-integrin, phosphorylated-Src (pTyr416; p-Src), pan-Src, Hemagglutinin
(HA)-tagged K-RasV12 (HA-K-RasV12) and tubulin. (b) FACS analysis of surface expressed α6-integrin in WT (left panel; blue) and K-RasV12 (left
panel; red) MDCK cells or α6-KO1/K-RasV12 (right panel; blue) and α6-KO2/K-RasV12 (right panel; red). Unlabeled cells (only secondary antibody)
are shown in gray. (c) Confocal sections of WT-, K-RasV12- and α6-KO/K-RasV12-MDCK cells stained for K-RasV12 (HA-K-RasV12),
Tyr416-phosphorylated-Src (p-Src) and total Src (pan-Src). Nuclei were visualized by 2-(4-amidinophenyl)-1H -indole-6-carboxamidine (DAPI).
Scale bars= 100 μm. (d) WT-, K-RasV12, α6-KO1/K-RasV12 and α6-KO2/K-RasV12-MDCK cells were grown in soft agar and colony formation
efﬁciency was determined as previous described.68 Scale bars= 100 μm. (e) Quantiﬁcation of colony formation in WT, K-RasV12, α6-KO1/K-
RasV12 and α6-KO2/K-RasV12 MDCK cells cultured in soft agar for 15 days. (f) Representative images of whole lungs from mice injected with
GFP-expressing WT-, K-RasV12 and α6-KO1/K-RasV12-MDCK cells using IVIS Spectrum imaging system (upper panel). Representative
ﬂuorescence microscopy images of cryosections from lungs (lower panels). Scale bars= 100 μm. (g) Quantiﬁcation of lung metastases as area
of GFP-positive colonies relative to the total lung tissue area. Data are presented as the mean± s.d. At least 10 randomly selected slides were
analyzed per each sample. Statistical signiﬁcance was determined using two-tailed t-test. *P-valueso0.05, **P-valueso0.01 and
***P-valueso0.001.
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cells (Figure 5i). These data show that K-RasV12 activates the
MAPK/ERK pathway leading to FOSL1 binding to ITGA6 promoter,
thereby inducing transcription of ITGA6 (Figure 5j). Importantly, all
the functional phenotypes observed for K-RasV12/α6-KO MDCK
cells, such as the loss of anoikis resistance, inhibition of
proapoptotic Bax expression and reduced lung colonization when
compared with K-RasV12 MDCK cells, could be replicated using
K-RasV12/FOSL1-KO cells (Supplementary Figures 5 and 6).
Restoration of αV-integrin expression in K-RasV12-transformed cells
results in EMT
Several subunits belonging to the αV-class integrins were down-
regulated in K-RasV12 MDCK cells (Figures 2c–e). αV-integrins have
been implicated in cellular mechanotransduction and they are
known to bind to and activate latent TGF-β1, thereby contributing
to EMT, presumably via activation of Src/focal adhesion kinase
pathway.38 In light of these data, downregulation of αV-class
integrins K-RasV12-cells seems counterintuitive. However, this
could be a cell intrinsic regulatory mechanism in non-
tumorigenic MDCK cells to restrict cell transformation. Moreover,
loss of epithelial polarity and integrity in vivo is often linked with
tumor-associated inﬂammation and ﬁbrosis that in turn is known
to induce αV-integrin expression in epithelial cells.38,39 In order to
clarify the possible role of αV-class integrins in K-RasV12-driven
transformation, we utilized an ectopic cytomegalovirus-based
promoter to overexpress αV-integrin fused to red ﬂuorescent
protein (αV-RFP) in both WT- and K-RasV12-MDCK cells. The MDCK
cells expressing both K-RasV12 and αV-integrins displayed striking
phenotypic differences when compared with other cell lines, as
they appeared to loose extensive E-cadherin-positive cell–cell
contacts and acquired an elongated mesenchymal morphology
(Figure 6a). Immunoﬂuorescence and western blot studies
conﬁrmed downregulation of E-cadherin and upregulation of
vimentin, suggesting that overexpression of K-RasV12 and αV-RFP
synergistically induced EMT in MDCK cells (Figures 6a and b). The
Figure 4. Knockout of α6-integrin promotes anoikis in K-RasV12-MDCK cells. (a) Confocal sections of WT-, K-RasV12-, α6-KO1/K-RasV12- and α6-
KO2/K-RasV12-MDCK cells cultured for 3 (upper panel) or 6 days (lower panel) in 3D Matrigel matrix substrate and stained for active-caspase 3
(green). Nuclei were counterstained with 2-(4-amidinophenyl)-1H -indole-6-carboxamidine (DAPI) (blue) and F-actin was stained with TRITC-
phalloidin (red). (b) Quantiﬁcation of cleaved-caspase-3-positive cysts in WT-, K-RasV12-, α6-KO1/K-RasV12- and α6-KO2/K-RasV12-MDCK 3D
cultured cysts. (c and d) Anoikis in WT, K-RasV12 cells and α6-KO/K-RasV12 cells grown on polyHEMA-coated plates for 24 h was evaluated by
Annexin-V/propidium iodide staining. Data are presented as the mean± s.d. and comes from three independent experiments. Statistical
signiﬁcance was determined using two-tailed t-test. *P-valueso0.05, **P-valueso0.01 and ***P-valueso0.001. (e) Western blot analysis of
pro-apoptotic protein Bax and apoptosis marker cleaved caspase-3 in WT, K-RasV12 cells and α6-KO/ K-RasV12 cells grown on polyHEMA-
coated plates for 24 h.
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Figure 5. K-RasV12 upregulates α6-integrin expression via MAPK/ERK/FOSL1 pathway. (a) MDCK cells were transduced with HA-K-RasV12,
cultured for 8 days with dimethyl sulfoxide (DMSO) (0.05%) or PD98059 (10 μM in 0.05% DMSO) and subjected to immunoblotting with
antibodies against α6-integrin, β4-integrin, phospho-ERK1/2 (p-ERK), total ERK (Pan-ERK), HA (HA-K-RasV12) or tubulin. (b) FACS analysis of the
surface expressed α6-integrin in mock (DMSO; red) or PD98059 (10 μM; blue)-treated K-RasV12-MDCK cells. (c) Confocal section of mock (DMSO)
and PD98059 (10 μM)-treated K-RasV12 MDCK cells stained for α6-integrin (red). Nuclei were counterstained with 2-(4-amidinophenyl)-1H
-indole-6-carboxamidine (DAPI) (blue). Scale bars= 100 μm. (d) Relative mRNA expression levels of selected integrin subunits in mock (DMSO,
white) and PD98059 (10 μM; black)-treated K-RasV12-MDCK cells. (e) Immunoblotting of FOSL1 and FOS in WT- and K-RasV12-MDCK cells.
Tubulin antibody was used as a loading control. (f) Mock (DMSO)- or PD98059 (10 μM)-treated K-RasV12-MDCK cells were subjected to
immunoblotting as described in (f). (g) WT and K-RasV12-MDCK cells were subjected for chromatin immunoprecipitation (ChIP)-qPCR analysis
using either FOSL1- (left panel) or FOS- (right panel) antibodies and primers amplifying selected regions at the α6-integrin promoter. Data are
presented as the mean± s.d. and come from three independent experiments. Statistical signiﬁcance was determined using two-tailed t-test.
*P-valueso0.05, **P-valueso0.01 and ***P-valueso0.001. (h) Luciferase reporter assays showing increased transcriptional activity of
α6-integrin promoter upon ectopic expression of FOSL1 in MDCK cells. Data are presented as the mean± s.d. and come from three
independent experiments. Statistical signiﬁcance was determined using two-tailed t-test. *P-valueso0.05, **P-valueso0.01 and
***P-valueso0.001. (i) Western blot analysis of K-RasV12-and FOSL1-KO/K-RasV12-MDCK cells with antibodies against α6-integrin, FOSL1, HA
(HA-K-RasV12) and tubulin. (j) Schematic model of K-RasV12-mediated upregulation of α6-integrin expression through activation of the
MAP/ERK/FOSL1-cascade to stimulate α6-integrin transcription and inhibit Bax expression. α6-integrin-dependent signaling crosstalk between
K-RasV12 and Src is also indicated.
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invasive properties of K-RasV12/αV-RFP-MDCK cells were especially
evident when they were grown in 3D Matrigel cultures, where
they migrated to form interconnected cellular networks without
obvious polarity or lumen (Figures 6c and d). Whereas K-RasV12-
MDCK cells proliferated with accelerated kinetics, the growth rate
of K-RasV12/αV-RFP-MDCK cells was signiﬁcantly slower when
compared with WT-MDCK cells or cells expressing only αV-RFP
(Figure 6e). Moreover, wound-healing assay revealed that αV-RFP
and K-RasV12 synergistically induced cell migration (Figures 6f and g).
In the single-cell transformation assay, it was found that basal
outgrowth was clearly favored over apical extrusion by αV-RFP-
expressing K-RasV12 cells (Supplementary Figure 7).
Figure 6. K-RasV12 and αV-integrins synergize to induce EMT in MDCK cells (a) Confocal section of WT-, αV-RFP-, K-RasV12- and K-RasV12/αV-RFP-
MDCK cells stained for vimentin (green; upper panels), E-cadherin (green; lower panels). Nuclei were counterstained with DAPI (blue). Scale
bars, 100 μm. (b) Immunoblotting of WT-, αV-RFP-, K-RasV12- and K-RasV12/αV-RFP-MDCK cells with antibodies against αV-integrin, HA (HA-K-
RasV12), vimentin, E-cadherin and actin. (c) Confocal sections of WT-, αV-RFP-, K-RasV12- and K-RasV12/αV MDCK cells grown as 3D cyst cultures
are shown. For confocal microscopy cysts were stained for vimentin (green; upper panels) or E-cadherin (green; lower panels). (d)
Quantiﬁcation of lumen formation in the 3D cultures. Data is combined from at least three independent experiments (n~ 100 for each
condition). Scale bar, 50 μm. Data are presented as the mean± s.d. and comes from three independent experiments. (e) Cell proliferation was
measured at the indicated time points by XTT colorimetric assay (absorbance at 450 nm (OD 450); mean± s.d. of ﬁve independent
experiments). (f) Wound-healing assay of WT, αV-RFP-, K-RasV12- and K-RasV12/αV-RFP-MDCK cells. (g) Relative rates of cell migration was
determined from three independent wound healing experiments. Statistical signiﬁcance was assessed using two-tailed t-test. P-values o0.05
are signiﬁed by (*), o0.01 by (**) and o0.001 by (***). Scale bar, 150 μm. Data are presented as the mean± s.d. and comes from three
independent experiments.
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K-RasV12 synergize with αV-integrins to induce EMT via activation
of TGF-β pathway
To study in more detail the transcriptional program triggered in
K-RasV12/αV-RFP-MDCK cells an RNA-seq based transcriptomic
analysis was performed comparing K-RasV12 cells expressing or not
αV-RFP (Figure 7a and Supplementary Table 1b). PANTHER analysis
highlighted ECM-mediated signaling as the most signiﬁcantly
modiﬁed pathway (Figure 7b). Given the observed EMT in
K-RasV12/αV-RFP cells, we focused our analysis on the known
EMT-inducing transcription factor genes SNAI1, SNAI2, ZEB1, ZEB2,
TWIST1 and TWIST2, all of which have been implicated in cancer
cell metastasis.40 Although RNA-Seq analysis identiﬁed only ZEB1
as a gene highly upregulated by K-RasV12/αV-RFP co-expression, a
qPCR analysis detected more than 395-fold upregulation of
TWIST1 and 5.5-fold upregulation of SNAI2 (Figure 7c). Taken
together, these data show that αV-integrins cooperate with
Figure 7. K-RasV12 and αV-integrins induce EMT via activation of TGF-β pathway in MDCK cells. (a) Heat-map representation of RNA-Seq
analysis of K-RasV12- and K-RasV12-expressing MDCK cells showing differentially expressed transcripts (42-fold; Po0.05). Deeper color
indicates higher expression level. FPKM, fragments per kilo-base per million mapped fragments. (b) PANTHER pathway ontology analysis
showing the most signiﬁcantly affected biological processes modulated by αV-RFP expression in K-RasV12-MDCK cells (Po0.05). (c) qPCR
analysis of EMT-related TF mRNA expression levels in K-RasV12 and K-RasV12/α-RFP-MDCK cells. (d) Western blot analysis was performed to
detect Smad2/3, Phospho-Smad2/3 and tubulin in K-RasV12 and K-RasV12/αV-RFP-MDCK cells. (e) Western blot analysis was performed to
detect E-cadherin, vimentin, Smad2/3, Phospho-Smad2/3 and tubulin in K-RasV12/αV-RFP-MDCK cells treated with dimethyl sulfoxide (DMSO)
or TGF-β inhibitor A83-01. (f) Confocal section of K-RasV12/αV-RFP-MDCK cells treated with DMSO or TGF-β inhibitor A83-01 and stained for
E-cadherin (green; upper panels) or vimentin (green; lower panels). Nuclei were counterstained with 2-(4-amidinophenyl)-1H -indole-6-
carboxamidine (DAPI) (blue). Scale bars= 50 μm. (g) Confocal sections (left and right panels) of 3D cyst cultures of K-RasV12/αV MDCK cells
treated with DMSO or TGF-β inhibitor A83-0. Cysts were stained for F-actin (red) and nuclei were counterstained with DAPI (blue). Scale
bars= 50 μm. (h) Quantiﬁcation of cyst phenotypes in the 3D cultures from g. Data are combined from at least three independent experiments
(n~ 100 for each condition). Scale bar= 50 μm. Data are presented as the mean± s.d.
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K-RasV12 to drive EMT likely through upregulation of TWIST1, ZEB1
and SNAI2 expression. K-RasV12 expression alone rendered MDCK
cells anoikis-resistant but failed to induce EMT due to efﬁcient
downregulation of αV-class integrins. Previous studies show that
αV-integrins modulate the activation of TGF-β signaling, such as
active latent TGF-β.41 We could show induced Smad2/3 phos-
phorylation in αV-RFP-expressing K-RasV12-MDCK cells (Figure 7d).
Next, we used a TGF-β inhibitor (A83-01) to inhibit TGF-β-signaling
in K-RasV12/αV-RFP-MDCK cells (Figure 7e). Interestingly, A83-01
treatment not only inhibited Smad-phosphorylation but it also
upregulated E-cadherin expression and led to formation of
extensive E-cadherin-positive adherens junctions (Figures 7e and
f). Remarkably, the invasive behavior of K-RasV12/αV-RFP-MDCK
cells in 3D Matrigel was essentially blocked (Figures 7g and h).
Therefore, we concluded that re-expression of αV-integrins in
K-RasV12-MDCK cells led to autocrine activation of TGF-β signaling
resulting in EMT.
α6-integrin, FOSL1 and αV-integrins are co-expressed in
aggressive human cancers harboring activating K-Ras mutations
To assess whether high expression levels of α6-integrin and FOSL1
may underlie K-Ras-driven human cancer progression, we
performed an analysis of human cancer cell lines whose K-Ras
mutation status has been documented. Gene expression analysis
was done by combining data from 522 cancer cell lines with WT
K-Ras and 76 cell lines with mutated K-Ras.42 Notably, we
observed robustly elevated levels of both α6-integrin and FOSL1
expression in K-Ras mutant human cancer cell lines (Figure 8a).
Similarly, αV-expression was signiﬁcantly upregulated in mutant
K-Ras-expressing cell lines. To analyze the potential relevance of
high expression levels of these genes for cancer progression in
patients, we went on to analyze publicly available clinical cancer
data sets. Analysis of The Cancer Genome Atlas data sets using
cBioportal platform for cross-cancer alteration and expression
Figure 8. High levels of α6-integrin, FOSL1 or αV-integrin expression correlate with aggressive phenotypes in mutant K-Ras-driven human
cancers. (a) ITGA6, FOSL1 and ITGAV mRNA expression was determined from cancer cell lines with either WT K-Ras (n= 522) or with K-Ras
mutation (n= 76) from the Garnett et al.42 cancer cell line data set. Gene expression intensity is shown as the log2 median-centered intensity,
as reported in Oncomine.69 (b) Kaplan–Meier plots showing the survival of pancreatic adenocarcinoma patients (PAAD) and (c) lung
adenocarcinoma (LUAD) patients with either high (top 10% highest expression; n= 20 for PAAD; n= 44 for LUAD) or low (bottom 10% lowest
expression; n= 18 for PAAD; n= 37 for LUAD) expression of ITGA6, FOSL1 and ITGAV. (queried from TCGAbrowser45).
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analysis for K-Ras revealed that, among the 20 types of cancers in
the database, pancreatic cancer and lung cancer had clearly the
highest rate of sequenced K-Ras mutations and expressed K-Ras at
high level (Supplementary Figure 8).43,44 Therefore, pancreatic
adenocarcinomas and lung adenocarcinomas were selected for
further analysis to explore whether the expression levels of α6-
integrin, FOSL1 and αV-integrin were correlated with cancer
progression and aggressiveness. The clinical relevance of α6-
integrin, FOSL1 and αV-integrin upregulation was visualized by
using Kaplan–Meier analysis with clinical survival data from a
collection of 179 pancreatic and 516 lung cancer (adenocarci-
noma) samples from TCGAbrowser,45 respectively. Strikingly, high
levels of α6-integrin, FOSL1 and αV-integrin expression were all
correlated with signiﬁcantly reduced survival of both in pancreatic
cancer and lung cancer patients when compared with patients
with low level expression of the same genes (Figure 8).
DISCUSSION
Here we report that K-RasV12-mediated transformation can over-
come the suppressive effect of polarized epithelial microenviron-
ment leading to basal outgrowth or apical cell extrusion. Survival
of extruded cells without proper ECM contact depended on α6-
integrins whose expression was upregulated in K-Ras12V-trans-
formed cells through activation of MAPK/ERK/FOSL1 pathway.
High levels of α6-integrins have been found to be expressed in
adult stem cells and in cancer stem cells.46–48 α6-integrin
expression correlates with enhanced proliferation capacity,
spheroid formation and, in the case of cancer stem cells, tumor
initiation upon xenografting.49,50 These data are in agreement
with the K-RasV12-induced α6-integrin-dependent anoikis resis-
tance and increased metastatic potential observed in our
current study.
Ras/MAPK/ERK pathway is important for growth of many types
of cancer cells and it has been implicated in stemness signaling.51
Here we show that K-Ras/MAPK/ERK signaling cascade induces
FOSL1 expression that in turn binds to α6-integrin promoter to
stimulate transcription of α6-integrin. FOSL1 is also highly
expressed in many epithelial cancers but its role during
tumorigenesis is less clear, except that FOSL1 is thought to
contribute to the regulation of EMT-associated transcription
factors.52 Importantly, Ras signaling and EMT-inducing TGF-β
signaling have been shown to collectively regulate epithelial cell
plasticity and invasive migration.53 Our data not only corroborate
these ﬁndings but we also demonstrate that two distinct integrins
are essential mediators of this signaling interplay. We show here
that although K-RasV12-induced expression of α6-integrin pro-
moted anchorage-independent growth, the ability of K-RasV12 to
trigger invasive behavior and EMT depended on αV-integrin
expression, which upregulated expression of TWIST1, ZEB1 and
SNAI2. Altered αV-integrin functions have been observed in many
types of cancer and in most cases αV-integrins modulate the
activation of growth factor receptor signaling, including TGF-β.54
In particular, αV-integrins are directly involved in the activation of
large latent TGF-β complex.55 Curiously, we observed down-
regulation of αV-integrins in K-RasV12-transformed MDCK cells. In
contrast, most cancer cells display elevated αV-integrin expression
levels that also correlated with poor prognosis in mutant K-Ras-
driven adenocarcinomas (Figure 8). The observed αV-integrin
downregulation might represent a cell intrinsic mechanism, still
intact in MDCK cells, which limits uncontrolled proliferation driven
by constitutive K-Ras signaling. Inhibition of MAPK/ERK pathway
partially restored αV-integrin expression in K-RasV12-MDCK cells
(Figure 5a). FOSL1, as part of SP1 transcription factor complex, has
been reported to inhibit transcription of ITGAV and ITGB3 in
normal endothelial cells.56 However, the mRNA levels of αV-
integrins were not affected in K-RasV12-MDCK cells, suggesting an
indirect regulatory mechanism that regulates the stability of αV-
integrins at protein level. The molecular machinery by which
K-RasV12 inhibits αV-integrin levels is likely to be complex but it
deﬁnitely warrants future research. The important ﬁnding in the
current study is that re-expression of αV-integrins is sufﬁcient to
induce EMT in K-RasV12-transformed cancer cells and might thus
represent a second key mutagenesis hit that converts TGF-β from
tumor suppressor to tumor-promoting factor.57
In conclusion, our data clariﬁes the molecular mechanisms by
which K-RasV12 mediates cell transformation and identiﬁes FOSL1,
ZEB1 and TWIST1 as crucial transcription factors regulated by
oncogenic K-RasV12. Importantly, our data shows that efﬁcient
K-RasV12-mediated cell transformation depends on balanced
activation of both α6- and αV-integrins, which promote anoikis
resistance and invasive phenotype, respectively, to drive metas-
tasis and aggressive tumorigenesis with poor prognosis. These
ﬁndings may allow development of novel strategies to interfere
with oncogenic properties of K-RasV12 and thereby tackle mutant
K-Ras-driven cancers that are generally difﬁcult to treat.
MATERIALS AND METHODS
Cell culture and viral transduction
MDCK II cells (Heidelberg strain) were a kind gift from Dr K Simons (MPI-
CBG, Dresden, Germany). Cells were grown in MEM media (Life
Technologies, Thermo Fisher Scientiﬁc, Helsinki, Finland) supplied with
5% fetal bovine serum (Life Technologies, Thermo Fisher Scientiﬁc) and 1%
penicillin/streptomycin (Life Technologies, Thermo Fisher Scientiﬁc), as
described previously.17 Viral supernatants were generated by transfecting
human embryonic kidney 293T cells (ATCC, LGC Standards GmbH, Wesel,
Germany; CRL-11268) with the lentiviral transfer plasmids in combination
with second-generation lentivirus packaging system58 using Lipofectamine
2000 (Invitrogen, Thermo Fisher Scientiﬁc). For ectopic expression, we
constructed a pLVET-IRES-GFP vector from pLVET-tTR-KRAB (11644,
Addgene, Cambridge, MA, USA)59 by replacing GFP-ttR-KRAB cassette
with an IRES-GFP cassette from pMSCV-PIG (21654, Addgene).60 cDNAs of
β-catenin4A, K-RasV12 and H-RasV12 were ampliﬁed by PCR from, E[beta]C
(Addgene plasmid 24312),21 MSCV-H-RasV12-IRES-GFP (Addgene plasmid
18780) and pLenti-PGK-KRAS4B(V12) (Addgene plasmid 35633),61 respec-
tively, and subsequently cloned using PmeI/BamHI/EcoRI sites in pLVET-
IRES-GFP vector. HA-HIF2α-P405A/P531A-pBabe-Hygro was a gift from
William Kaelin (Addgene plasmid 21676).22 MSCV-hygro-F-Ezh2 (Addgene
plasmid 24926)62 and pHIV-H2B-mRFP (Addgene plasmid 18982)63 were
obtained from Addgene. cDNA of αV-integrin was ampliﬁed by PCR from
pTag RFP-αV-integrin (EVROGEN, BioCat GmbH, Heidelberg, Germany) and
cloned into RVH1-puro64 vector using XbaI and NotI . The cloning primers
are listed in Supplementary Table 3. For CRISPR/Cas9 knockout,
lentiCRISPR-v2 (Addgene plasmid 52961)29 was used. LentiCRISPR/α6-KO
and lentiCRISPR/ FOSL1-KO plasmids were constructed as described
previously.29 The DNA oligonucleotides used for gRNAs are listed in
Supplementary Table 4.
Antibodies and reagents
All primary antibodies used are listed in Supplementary Table 2. Cy3- and
horseradish peroxidase-conjugated secondary antibodies were all from
Jackson Immunochemicals (LABNET OY, Helsinki, Finland) and Alexa488-
conjugated secondary antibodies were from Invitrogen. TRITC-Phalloidin
and 2-(4-amidinophenyl)-1H -indole-6-carboxamidine were purchased
from Sigma-Aldrich (Merck, Helsinki, Finland). Hygromycin B and
Puromycin were from Thermo Fisher Scientiﬁc (Helsinki, Finland). dimethyl
sulfoxide was from Sigma-Aldrich. The MEK inhibitor PD98059 was from LC
Laboratories (Woburn, MA, USA). The PI (3) K inhibitor Pictilisib was from
Selleck Chemicals (SMS Gruppen, Rungsted, Denmark).
Three-dimensional cell culture
Three-dimensional overlay cultures were carried out as previously
described.9 Brieﬂy, 150 μl of Matrigel matrix (354230, BD Biosciences,
Becton Dickinson Oy, Vantaa, Finland) was allowed to gel at 37 °C on a
35 mm glass-bottom μ-Dish (81158, IBIDI, Mediq Suomi Oy Laboratory
Products, Espoo, Finland) suitable for ﬂuorescence microscopy. Cells were
seeded at ~ 5000 cells per dish in medium containing 2% (v/v) Matrigel
matrix. Medium was replaced every 2 days with fresh medium containing
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2% Matrigel matrix. For analysis, random ﬁelds were examined such that a
minimum of 100 cysts per each condition were scored.
Immunoﬂuorescence
For immunoﬂuorescence analysis, cells were ﬁxed in PBS-3% paraformal-
dehyde for 20 min at room temperature, permeabilized with PBS-0.2%
Triton X-100 and quenched with PBS-100 mM glycine, and then blocked
with IF buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 7.7 mM NaN3,
0.1% bovine serum albumin, 0.2% Triton X-100 and 0.05% Tween-20) for
50 min at room temperature. Samples were incubated with primary
antibodies (see Supplementary Table 1 for details) in IF buffer overnight at
4 °C, rinsed three times with IF buffer at room temperature with gentle
rocking, incubated with ﬂuorescent-conjugated secondary antibody in IF
buffer for 1 h at room temperature, washed three times with PBS,
incubated 15 min with PBS containing 2-(4-amidinophenyl)-1H -indole-6-
carboxamidine (Sigma-Aldrich), washed once with PBS and then mounted
with ImmuMount (Thermo Scientiﬁc). Confocal laser scanning microscopy
images were acquired by using a Zeiss LSM 780 confocal microscope, × 40
Plan-Apochromat objective (numerical aperture = 1.4). Stacks of 1.5 μm
were acquired with 100 nm increments from the basal region of cells
containing matrix adhesions and analyzed with the ZEN 2011 software.
Live-cell imaging
MDCK cells stably expressing H2B-mRed were set up for 3D culture in
35 mm glass-bottom μ-Dish (81158, IBIDI). Live imaging was performed
with a custom-built spinning disk confocal system based on Zeiss spinning
disc confocal microscopy with a spinning disc unit (Yokogawa CSU-X1),
Hamamatsu electron-multiplying charge-coupled device camera and
humidiﬁed, environmental control incubator (37 °C, 5% CO2). Images were
acquired starting ~ 36 h after virus infection. Image stacks of complete
cysts were captured with a EC Plan NeoFluar × 40/0.75 DIC (air) objective
every 30 min for a duration of 48 h using Zen 2012 (Carl Zeiss Oy, Vantaa,
Finland; Blue edition) software and were analyzed with Zen 2012 (Blue
edition).
RNA-seq and data analysis
Total RNA was extracted from the cells using Trizol Reagent (15596026, Life
Technologies, Thermo Fisher Scientiﬁc). The concentration and quality of
RNA samples were determined using a Nano Drop 2000 micro-volume
spectrophotometer (Thermo Scientiﬁc). The library construction and
sequencing were performed by the Beijing Genomics Institute-Hongkong,
China (http://www.bgitechsolutions.com/), as described previously.65
Paired-end, 100 bp read-length sequencing was carried out using Illumina
HiSeq 2000 and 40 million reads were generated for each sample. The
RNA-seq reads were mapped to dog genome reference sequence (Broad
CanFam3.1) by using TopHat2. Cuffdiff was used for differential gene
expression analysis of RNA-seq data. Heatmap was generated by
CummeRbund in R, as described previously.66 RNA-seq data are deposited
at BioProject under accession number PRJNA382611.
Western blotting
Cells were lysed on ice in RIPA lysis buffer (50 mM Tris/HCl, pH 8.0, 250 mM
NaCl, 1% TritonX-100, 0.5% (w/v) sodium deoxycholate and 1 mM EDTA)
containing complete mini-protease inhibitor cocktail (Roche, Roche
Diagnostics Oy, Espoo, Finland). Lysates were sonicated and centrifuged
at 13 000 r.p.m. for 10 min, 4 °C. Protein concentrations were determined
with the BCA Protein Assay Kit (Pierce, Thermo Fisher Scientiﬁc). Proteins
were separated using SDS–polyacrylamide gel electrophoresis (MiniPro-
tean3 system, Bio-rad Laboratories, Helsinki, Finland) and transferred on
Protran nitrocellulose ﬁlters (Perkin-Elmer, Turku, Finland) and then
exposed to primary antibodies as described earlier.17 Horseradish
peroxidase-conjugated secondary antibodies were visualized using a
chemiluminescence kit (Pierce, Thermo Fisher Scientiﬁc) and LAS-3000
imaging system (Fuji-ﬁlm, Fuji Finland, Vantaa, Helsinki). Uncropped
original western blot full scans show in Supplementary Figure 9.
FACS analysis
For surface FACS, cells were incubated with rat anti-a6-integrin (555841, BD
Biosciences) in FACS buffer (0.5% bovine serum albumin in PBS) for 30 min
at 4 °C and then washed twice in FACS Buffer. Cells were incubated with
Alexa488-conjugated anti-mouse secondary antibodies (A-11001,
Invitrogen) for 15 min and then washed twice in FACS Buffer for 30 min
each at 4 °C. At least 10,000 cells were analyzed on a BD FACSCalibur cell
analyzer (BD Biosciences) and FACS data were computed using the
CellQuest software (Becton Dickinson Oy, Vantaa, Finland).
Soft agar assays
About 2000 WT-, K-RasV12-, α6-KO1/ K-RasV12- or α6-KO2/ K-RasV12-MDCK
cells were suspended in 1 ml of prewarmed 0.35% SeaPlaque agarose/
MEM/5% fetal bovine serum and pipetted on top of 1.5 ml of 0.7%
SeaPlaque agarose/MEM/5% fetal bovine serum gelled onto a well of a six-
well plate. Cells were incubated for 15 days, at 37 1C and 5% CO2, and fresh
medium was exchanged twice per week. All colonies formed in each of the
wells were imaged using an Olympus CellSens live-cell/time-lapse imaging
system at room temperature. ImageJ were used to segment the images
and count colonies that were larger than 100 μm in diameter.
Chromatin immunoprecipitation and qPCR
ChIP assays were carried out as previously described.58 Cells were cross-
linked in 1 % formaldehyde at room temperature for 10 min. The reaction
was terminated with 125 mM glycine solution for 5 min followed by cell
lysis and sonication (Q800R sonicator, QSonica, LLC., Newtown, CT, USA) to
generate chromatin fragments with an average size of 0.3 kb. FOSL1
(PCRP-FOSL1-1E3, Developmental Studies Hybridoma Bank, Iowa City,
IA, USA), FOS (sc-7202X, Santa Cruz Biotechnology, Thermo Fisher
Scientiﬁc, Vantaa, Finland) and control IgG (normal mouse IgG and normal
rabbit IgG, Jackson Immunochemicals) were used for the ChIP assay. ChIP
DNA was puriﬁed with the Mini-Elute PCR puriﬁcation kit (28006, Qiagen,
Evo, Finland), and analyzed by quantitative RT-PCR (CFX96 Real-Time
System, Bio-Rad) using primers targeting appropriate DNA sequences
corresponding to ITGA6 promoter region. Primer sequences used in this
work are listed in Supplementary Table 5. Statistical signiﬁcances were
calculated by two-tailed t-test.
Quantitative reverse transcriptase–PCR
Total RNA was isolated using the RNA easy column kit (Qiagen) according
to the manufacturer’s instructions. One microgram of total RNA per sample
was annealed with anchored oligo (dT) for cDNA synthesis using M-MuLV
Reverse Transcriptase (Thermo Scientiﬁc). qPCR was performed by using
Brilliant III Ultra-FAST SYBR Green qPCR master mix (Stratagene, AH
diagnostics Oy, Helsinki, Finland) and MX3005P (Stratagene), as described
previously. Only primers resulting in a single peak in the melting curve
analysis were used. The sequences of qPCR primers are listed in
Supplementary Table 5. Results are representative of three independent
experiments and difference. Signiﬁcance was calculated by two-tailed
t-test.
In vitro luciferase assay
DNA fragment of ITGA6 promoter (chr.36:16,775,314-16,776,486) was
inserted into the pGL3-Basic vector (E1751, Promega, Nacka, Sweden)
upstream of Luciferase gene. A control plasmid pGL75 or the α6-promoter
luciferase plasmid was co-transfected into MDCK cells and FOSL1-MDCK
cells (100 μl of 1.5 × 105 per well) using X-treme GENE HP DNA Transfection
Reagent (06366236001, Roche Applied Science, Roche Diagnostics Oy,
Espoo, Finland) in the 96-well white plate. After 48 h, Fireﬂy and Renilla
luciferase activities were measured with Dual-Glo Luciferase assay system
(E2940, Promega). The experiments were performed in triplicate. Cloning
primers are listed in Supplementary Table 3.
Assessment of anoikis In vitro
WT-, K-RasV12-, α6-KO/ K-RasV12- or FOSL1-KO/ K-RasV12-MDCK cells (1 × 106)
were seeded in polyHEMA pre-coated 10 cm plates at 37 °C for 24 h. The
cells were scratched from plate and wash with cold PBS for ﬂow cytometry
analysis by using an Annexin V-ﬂuorescein isothiocyanate/propidium
iodide kit (BD Pharmingen, Becton Dickinson Oy, Vantaa, Finland;
556547). Caspase-3 activity was measured using western blotting of a
cleaved-caspase-3 antibody and pro-apoptotic activity was detected using
Bax antibodies (Supplementary Table 2).
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Cancer metastasis in vivo model
Animal protocols were approved by the University of Oulu Animal Care.
The tail-vein of 7-week-old female 22 NOD.CB17-PrkdcSCID mice (six mice
for each cell lines, except four mice for GFP-K-RasV12 MDCK cells) were
injected with 1 × 106 cells (WT-GFP-, K-RasV12-GFP-, α6-KO1/K-RasV12-GFP-
and FOSL1-KO1/K-RasV12-GFP-MDCK cells) suspended in 150 μl of MEM
(ThermoFisher, 11095-080). Upon killing on 15 days (except for three mice
injected with K-RasV12-GFP-MDCK cells, which had to be killed earlier due
to their poor condition), lungs were dissected for in vivo optical imaging by
IVIS Spectrum (PerkinElmer). To image lung metastases, part of the
dissected lungs were embedded (Fisher Healthcare Tissue-Plus O.C.T
Compound, 23-730-571, Fisher & Paykel Healthcare AB, Helsinki, Finland)
for frozen tissue sections (Cryotome Leica CM3050S, Leica Microsystems,
Immuno Diagnostic Oy LMS, Espoo, Finland). GFP-positive areas were
determined by using Zeiss Axio Lab ﬂuorescence microscope (Carl Zeiss
Oy) and ImageJ software.67 In addition, the remaining parts of the
dissected lungs were ﬁxed in Bouin’s ﬁxative for 24 h and embedded with
parafﬁn for cross-sections and staining with hematoxylin and eosin
solution. Tumor area was determined by using Leica microscope and
ImageJ software.67
Cell proliferation and migration
For cell proliferation assay, about 1000 cells per well were seeded into
96-well plates and tested with the XTT kit (11465015001, Roche) at
designed time points by reading the absorbance at 450 nm, following
the manufacturer’s instructions. Values were obtained from four repli-
cate wells for each treatment and time point. For wound-healing assay,
we used a culture-insert two-well in 35 mm μ-Dish (81176, IBIDI). First,
cells were allowed to grow to conﬂuency, after which the IBIDI-insert
was removed using sterile tweezers. Time-lapse videos were recor-
ded from 0 to 16 h. Results are representative of three indepen-
dent experiments. Statistical signiﬁcance was calculated by two-tailed
t-test.
Statistical analysis
Normally distributed samples were tested for signiﬁcant differences with
one-way analysis of variance between two groups. A Student´s t-test
(unpaired, two-tailed) was used to determine signiﬁcant differences in
normalized samples, unless otherwise noted. Error bars denote s.d.
P-valueso0.05 were considered as signiﬁcant (*Po0.05, Po0.01 and
***Po0.001).
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